CStone Pharmaceuticals (HKG:2616) said the first patient was successfully dosed in the global multicenter Phase I clinical trial of its independently developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, without infusion reactions or other adverse events, according to a Tuesday filing with the Hong Kong Stock Exchange.
CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4 to boost the immune response against tumors. It is designed to reinvigorate exhausted immune cells while neutralizing VEGF, making it a potential breakthrough for various cancers, including lung, liver, and ovarian cancer, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.